Introduction 

CAR T-cell therapy is a potentially curative treatment that is currently available to treat certain types of aggressive and advanced blood cancers. However, many eligible patients do not get the opportunity to benefit from this treatment.

The CAR T Vision Steering Committee was established to tackle this challenge – bringing together leaders from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, and health technology assessment, policy and other subject matter experts. Its aim was to develop a Vision that would unite stakeholders behind shared goals with a renewed sense of urgency for action. This report is the first publication of the CAR T Vision Steering Committee. It details the Vision and how it was developed, the challenges to address, and the priority areas where progress is needed to make the Vision a reality.

The recommendations section includes imperatives to dramatically increase the proportion of eligible patients accessing CAR T-cell therapy. They provide the foundations for advocacy and action by local stakeholders to address the specific access challenges faced by patients in different geographies.